Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

Urology, renal & men’s healthPRM 0062
Dosage formTablets
Oral

Acetazolamide 250 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Urology & renal-health agent
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2156
Dosage formHard-gelatin capsules
Oral

Alfacalcidol 0.25 mcg, Calcium Carbonate 200 mg, Zinc 7.5 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Nutritional supplement
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0084
Dosage formTablets
Oral

Alfacalcidol 0.25 mcg, Calcium Citrate Malate 200 mg, Cupric Sulphate 1 mg, Magnesium Oxide 10 mg, Manganese Sulphate 1.8 mg, Sodium Tetraborate 250 mcg, Soya Isoflavonids 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nutritional supplement
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2646
Dosage formTablets
Oral

Alfuzosin 10 mg (ER)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-1 blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0085
Dosage formTablets
Oral

Alfuzosin 10 mg (PR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-1 blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0086
Dosage formTablets
Oral

Alfuzosin 10 mg, Dutasteride 0.5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-1 blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2647
Dosage formTablets
Oral

Alfuzosin Hcl. 10 mg, Dutasteride 0.5 mg (ER)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
5-alpha reductase inhibitor + Alpha-1 blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0087
Dosage formTablets
Oral

Allopurinol 100 mg Film Coated

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Urology & renal-health agent
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 880
Urology, renal & men’s healthPRM 0088
Dosage formTablets
Oral

Allopurinol 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Urology & renal-health agent
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2682
Dosage formTablets
Oral

Alpha-Hydroxymethionine Calcium Salt 59 mg, Alpha-Ketoisoleucine Calcium Salt 67 mg, Alpha-Ketoleucine Calcium Salt 101 mg, Alpha-Ketophenylalanine Calcium Salt 68 mg, Alpha-Ketovaline Calcium Salt 86 mg, Histidine 38 mg, L-Lysine Acetate 105 mg, Threonine 53 mg, Tryptophan 23 mg, Tyrosine 30 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Ketoanalogue / amino acid supplement for renal care + Amino acid / metabolic nutritional supplement
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2889
Dosage formTablets
Oral

Avanafil 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE5 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2890
Dosage formTablets
Oral

Avanafil 200 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE5 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 2891
Dosage formTablets
Oral

Avanafil 50 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE5 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 3070
Dosage formTablets
Oral

Calcium Acetate 435 mg, Magnesium Carbonate 235 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Phosphate binder
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 1682
Dosage formOral suspension
Oral

Calcium Carbonate 80 mg, Sodium Alginate 250 mg, Sodium Bicarbonate 133.5 mg / 5 ml

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Nutritional supplement
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 5468
Dosage formOral suspension
Oral

Calcium Polystyrene Sulphonate 15 gm / 60 ml

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Potassium-binding resin
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 5287
Dosage formSyrup
Oral

Citric Acid 334 mg, Potassium Citrate 1100 mg

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Urinary alkaliniser
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 1543
Dosage formSyrup
Oral

Citric Acid Monohydrate 334 mg, Potassium Citrate Monohydrate 1100 mg / 5 ml

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Urology & renal-health agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 3295
Dosage formTablets
Oral

Coral Calcium, L-Carnitine, Magnesium Aspartate, Potassium Citrate, Vitamins

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Urinary alkaliniser + Amino acid / metabolic nutritional supplement + Vitamin / mineral supplement + Mineral supplement
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0531
Dosage formTablets
Oral

Dapoxetine 30 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Urology & renal-health agent
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0532
Dosage formTablets
Oral

Dapoxetine 30 mg, Sildenafil 50 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE5 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0534
Dosage formTablets
Oral

Dapoxetine 30 mg, Tadalafil 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE5 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0535
Dosage formTablets
Oral

Dapoxetine 30 mg, Tadalafil 20 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
PDE5 inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Urology, renal & men’s healthPRM 0536
Dosage formTablets
Oral

Dapoxetine 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Urology & renal-health agent
Manufacturing stream
Non-beta-lactam
BCS class
Class II
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 109

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product